Cynosure Receives CE Mark for Smartlipo MPX(TM) Workstation
July 22 2008 - 8:30AM
PR Newswire (US)
Company to Launch Innovative Laser Lipolysis Technology in the
European Union WESTFORD, Mass., July 22 /PRNewswire-FirstCall/ --
Cynosure, Inc. (NASDAQ:CYNO), a leading developer and manufacturer
of a broad array of light-based aesthetic treatment systems, has
received the European CE Mark for Smartlipo MPX(TM), the company's
high-powered, dual-wavelength aesthetic workstation to liquefy fat
and tighten skin through collagen remodeling. The CE Mark certifies
that the Smartlipo MPX conforms to the essential health and safety
requirements of the European Medical Device Directive. Cynosure
expects to launch Smartlipo MPX through its subsidiaries in the
European Union beginning this quarter. Cynosure has marketed and
sold Smartlipo MPX in the United States since the second quarter of
2008. "The quality associated with the Smartlipo brand is an
important differentiator for Cynosure among U.S. customers and
consumers, and we expect this to be equally true as we introduce
Smartlipo MPX to the international market," said President and
Chief Executive Officer Michael Davin. "We believe the integration
of our MultiPlex(TM) technology and SmartSense(TM) intelligent
delivery system makes Smartlipo MPX the ideal platform blending
body sculpting and tissue tightening through coagulation. Together,
these applications are forecast to help drive the global aesthetic
market from $8.4 billion in 2007 to more than $15 billion by
2011(1). We expect that our continued focus on innovation will
enable Cynosure to remain at the forefront of this high-growth
market." "The EU represents the next phase of our multi-pronged
strategy to expand the geographic reach of our Smartlipo
technology," Davin said. "Smartlipo MPX training for our European
subsidiaries is already underway, and they are eager to introduce
the product in their markets. This rollout will be followed by a
targeted launch in select countries in the Middle East, as well as
ongoing submissions for regulatory approvals in the Asia Pacific
region." About Cynosure, Inc. Cynosure, Inc. develops and markets
aesthetic treatment systems that are used by physicians and other
practitioners to perform non-invasive and minimally invasive
procedures to remove hair, treat vascular lesions, rejuvenate skin
through the treatment of shallow vascular and pigmented lesions,
laser lipolysis and temporarily reduce the appearance of cellulite.
Cynosure's products include a broad range of laser and other
light-based energy sources, including Alexandrite, pulsed dye,
Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure
was founded in 1991. For corporate or product information, contact
Cynosure at 800-886-2966, or visit http://www.cynosure.com/.
Forward-Looking Statements Any statements in this press release
about future expectations, plans and prospects for Cynosure, Inc.,
including statements about the company's expectations regarding the
performance and market acceptance of the Smartlipo MPX and future
financial performance, as well as other statements containing the
words "believes," "anticipates," "plans," "expects," "will" and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including market acceptance of the Smartlipo MPX,
Cynosure's reliance on sole source suppliers, the inability to
accurately predict the timing or outcome of regulatory decisions,
changes in consumer preferences, competition in the aesthetic laser
industry, economic, market, technological and other factors
discussed in Cynosure's most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, each of which is filed with the
Securities and Exchange Commission. In addition, the
forward-looking statements included in this press release represent
Cynosure's views as of the date of this press release. Cynosure
anticipates that subsequent events and developments will cause its
views to change. However, while Cynosure may elect to update these
forward-looking statements at some point in the future, it
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Cynosure's views as of any date subsequent to the date
of this press release. (1) Medical Insight, Inc., Global Aesthetic
Market Study (2007) DATASOURCE: Cynosure, Inc. CONTACT: Scott
Solomon, Vice President of Sharon Merrill Associates, Inc. for
Cynosure, Inc., +1-617-542-5300, Web site: http://www.cynosure.com/
Copyright
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From May 2024 to Jun 2024
Cynosure (NASDAQ:CYNO)
Historical Stock Chart
From Jun 2023 to Jun 2024